Literature DB >> 7016688

Impaired glucose tolerance and growth hormone in chronic liver disease.

W J Riley, V J McCann.   

Abstract

Of 30 patients with chronic liver disease 16 showed some degree of impairment of glucose tolerance, and 16 patients had lack of suppression of raised fasting growth hormone levels or showed an anomalous rise after oral glucose. No relationship, however, existed between the state of glucose tolerance and the presence of abnormal growth hormone levels. Plasma glucose in those with normal growth hormone response at 0, 1/2, 1, 1-1/2, and 2 hours, after 50 g glucose were 5.55 +/- 0.41 mmol/l, 8.71 +/- 0.59, 10.66 +/- 0.99, 10.28 +/- 1.37, 8.90 +/- 1.40 (mean +/- SEM; n = 14). Under the same conditions those with abnormal growth hormone responses showed values of 5.32 +/- 0.59, 7.83 +/- 0.81, 9.41 +/- 0.95, 9.46 +/- 0.99, 8.69 +/- 0.98. At no time were the differences significantly different as judged by Student's t test. Measurement of serum insulin indicated a relative deficiency in patients with impaired tolerance. It is concluded that the abnormal growth hormone is not directly responsible for the impaired glucose tolerance.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7016688      PMCID: PMC1419153          DOI: 10.1136/gut.22.4.301

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  11 in total

1.  Glucose tolerance and diabetes in chronic liver disease.

Authors:  C Megyesi; E Samols; V Marks
Journal:  Lancet       Date:  1967-11-18       Impact factor: 79.321

2.  Histocompatibility antigens in active chronic hepatitis and primary biliary cirrhosis.

Authors:  R M Galbraith; A L Eddleston; M G Smith; R Williams; R N McSween; G Watkinson; H Dick; L A Kennedy; J R Batchelor
Journal:  Br Med J       Date:  1974-09-07

3.  HL-A antigens and diabetes mellitus.

Authors:  J Nerup; P Platz; O O Andersen; M Christy; J Lyngsoe; J E Poulsen; L P Ryder; L S Nielsen; M Thomsen; A Svejgaard
Journal:  Lancet       Date:  1974-10-12       Impact factor: 79.321

4.  Paradoxical elevation of growth hormone in active chronic hepatitis.

Authors:  M D Becker; G C Cook; A D Wright
Journal:  Lancet       Date:  1969-11-15       Impact factor: 79.321

5.  Behavior of pancreatic glucagon, insulin, and HGH in liver cirrhosis, after arginine and I.V. glucose.

Authors:  A V Greco; G Ghirlanda; C Patrono; G Fedili; R Manna
Journal:  Acta Diabetol Lat       Date:  1974 Jul-Aug

6.  Hepatic clearance of human growth hormone.

Authors:  A L Taylor; R L Lipman; A Salam; D H Mintz
Journal:  J Clin Endocrinol Metab       Date:  1972-02       Impact factor: 5.958

7.  Cirrhosis and diabetes. V. Serum human growth hormone levels in Laennec's cirrhosis.

Authors:  H O Conn; W H Daughaday
Journal:  J Lab Clin Med       Date:  1970-10

8.  Serum glucose, insulin, and growth hormone in chronic hepatic cirrhosis.

Authors:  N A Samaan; D B Stone; R D Eckhardt
Journal:  Arch Intern Med       Date:  1969-08

9.  Elevated basal growth hormone levels and growth hormone response to TRH in alcoholic patients with cirrhosis.

Authors:  A Zanoboni; W Zanoboni-Muciaccia
Journal:  J Clin Endocrinol Metab       Date:  1977-09       Impact factor: 5.958

10.  HL-A system and diabetes mellitus.

Authors:  A G Cudworth; J C Woodrow
Journal:  Diabetes       Date:  1975-04       Impact factor: 9.461

View more
  1 in total

1.  Mechanism of insulin resistance in human liver cirrhosis. Evidence of a combined receptor and postreceptor defect.

Authors:  P Cavallo-Perin; M Cassader; C Bozzo; A Bruno; P Nuccio; A M Dall'Omo; M Marucci; G Pagano
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.